Kymera Therapeutics Inc（KYMR）のニュースとイベントKYMRKymera Therapeutics Inc

Kymera Therapeutics Q2 Revenue $65M, Exceeds Expectations

Reports Q2 revenue $65M, consensus $32.78M. Collaboration revenues recognized in the second quarter of 2026 consisted of a $45M option exercise fee related to the company's collaboration with Gilead Sciences and a $20M milestone payment related to the company's collaboration with Sanofi. "Kymera is delivering in a pivotal period of execution, with multiple clinical-stage programs advancing, important data catalysts ahead, and growing conviction in the potential of oral degrader medicines to transform the standard of care for chronic, debilitating immunological diseases," said Nello Mainolfi, Founder, President and CEO, Kymera Therapeutics. "The rapid completion of enrollment in our KT-621 BROADEN2 Phase 2b trial in atopic dermatitis nearly six months ahead of our original timeline is a powerful example of the immense interest from clinicians and patients in a once-daily oral therapy and excellent execution from the Kymera team. The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options."